Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 390

1.

Prior stroke and transient ischemic attack as risk factors for subsequent stroke in atrial fibrillation patients: A report from the GARFIELD-AF registry.

Hacke W, Bassand JP, Virdone S, Camm AJ, Fitzmaurice DA, Fox KA, Goldhaber SZ, Goto S, Haas S, Kayani G, Mantovani LG, Misselwitz F, Pieper KS, Turpie AG, van Eickels M, Verheugt FW, Kakkar AK; GARFIELD-AF Investigators.

Int J Stroke. 2019 Dec 17:1747493019891516. doi: 10.1177/1747493019891516. [Epub ahead of print]

PMID:
31847794
2.

New AI Prediction Model Using Serial PT-INR Measurements in AF Patients on VKAs: GARFIELD-AF.

Goto S, Goto S, Pieper KS, Bassand JP, Camm AJ, Fitzmaurice DA, Goldhaber SZ, Haas S, Parkhomenko A, Oto A, Misselwitz F, Turpie AGG, Verheugt FWA, Fox KAA, Gersh BJ, Kakkar AK; GARFIELD-AF Investigators.

Eur Heart J Cardiovasc Pharmacother. 2019 Dec 10. pii: pvz076. doi: 10.1093/ehjcvp/pvz076. [Epub ahead of print]

PMID:
31821482
3.

The association between patterns of atrial fibrillation, anticoagulation, and cardiovascular events.

Atar D, Berge E, Le Heuzey JY, Virdone S, Camm AJ, Steffel J, Gibbs H, Goldhaber SZ, Goto S, Kayani G, Misselwitz F, Stepinska J, Turpie AGG, Bassand JP, Kakkar AK; GARFIELD-AF Investigators.

Europace. 2020 Feb 1;22(2):195-204. doi: 10.1093/europace/euz292.

4.

Isolated Distal Deep Vein Thrombosis: Perspectives from the GARFIELD-VTE Registry.

Schellong SM, Goldhaber SZ, Weitz JI, Ageno W, Bounameaux H, Turpie AGG, Angchaisuksiri P, Haas S, Goto S, Zaghdoun A, Farjat A, Nielsen JD, Kayani G, Mantovani LG, Prandoni P, Kakkar AK.

Thromb Haemost. 2019 Oct;19(10):1675-1685. doi: 10.1055/s-0039-1693461. Epub 2019 Aug 1.

5.

Outcomes in Newly Diagnosed Atrial Fibrillation and History of Acute Coronary Syndromes: Insights from GARFIELD-AF.

Verheugt FWA, Ambrosio G, Atar D, Bassand JP, Camm AJ, Costabel JP, Fitzmaurice DA, Illingworth L, Goldhaber SZ, Goto S, Haas S, Jansky P, Kayani G, Stepinska J, Turpie AGG, van Eickels M, Kakkar AK; GARFIELD-AF Investigators.

Am J Med. 2019 Dec;132(12):1431-1440.e7. doi: 10.1016/j.amjmed.2019.06.008. Epub 2019 Jul 12.

PMID:
31306621
6.

Patient Management Strategies and Long-Term Outcomes in Isolated Distal Deep-Vein Thrombosis versus Proximal Deep-Vein Thrombosis: Findings from XALIA.

Ageno W, Mantovani LG, Haas S, Kreutz R, Monje D, Schneider J, Bugge JP, Gebel M, Turpie AGG.

TH Open. 2019 Mar 26;3(1):e85-e93. doi: 10.1055/s-0039-1683968. eCollection 2019 Jan.

7.

Anticoagulation therapy patterns for acute treatment of venous thromboembolism in GARFIELD-VTE patients.

Haas S, Ageno W, Weitz JI, Goldhaber SZ, Turpie AGG, Goto S, Angchaisuksiri P, Dalsgaard Nielsen J, Kayani G, Zaghdoun A, Farjat AE, Schellong S, Bounameaux H, Mantovani LG, Prandoni P, Kakkar AK.

J Thromb Haemost. 2019 Oct;17(10):1694-1706. doi: 10.1111/jth.14548. Epub 2019 Jul 23.

PMID:
31220403
8.

Upper Extremity DVT versus Lower Extremity DVT: Perspectives from the GARFIELD-VTE Registry.

Ageno W, Haas S, Weitz JI, Goldhaber SZ, Turpie AGG, Goto S, Angchaisuksiri P, Dalsgaard Nielsen J, Kayani G, Farjat AE, Zaghdoun A, Schellong S, Bounameaux H, Mantovani LG, Prandoni P, Darius H, Kakkar AK.

Thromb Haemost. 2019 Aug;119(8):1365-1372. doi: 10.1055/s-0039-1688828. Epub 2019 Jun 10.

PMID:
31183844
9.

International longitudinal registry of patients with atrial fibrillation and treated with rivaroxaban: RIVaroxaban Evaluation in Real life setting (RIVER).

Beyer-Westendorf J, Camm AJ, Fox KAA, Le Heuzey JY, Haas S, Turpie AGG, Virdone S, Kakkar AK; RIVER Registry Investigators.

Thromb J. 2019 Apr 25;17:7. doi: 10.1186/s12959-019-0195-7. eCollection 2019.

10.

Predictors of NOAC versus VKA use for stroke prevention in patients with newly diagnosed atrial fibrillation: Results from GARFIELD-AF.

Haas S, Camm AJ, Bassand JP, Angchaisuksiri P, Cools F, Corbalan R, Gibbs H, Jacobson B, Koretsune Y, Mantovani LG, Misselwitz F, Panchenko E, Ragy HI, Stepinska J, Turpie AG, Sawhney JP, Steffel J, Lim TW, Pieper KS, Virdone S, Verheugt FW, Kakkar AK; GARFIELD-AF Investigators.

Am Heart J. 2019 Jul;213:35-46. doi: 10.1016/j.ahj.2019.03.013. Epub 2019 Apr 11.

11.

Analysis of Outcomes in Ischemic vs Nonischemic Cardiomyopathy in Patients With Atrial Fibrillation: A Report From the GARFIELD-AF Registry.

Corbalan R, Bassand JP, Illingworth L, Ambrosio G, Camm AJ, Fitzmaurice DA, Fox KAA, Goldhaber SZ, Goto S, Haas S, Kayani G, Mantovani LG, Misselwitz F, Pieper KS, Turpie AGG, Verheugt FWA, Kakkar AK; GARFIELD-AF Investigators.

JAMA Cardiol. 2019 Jun 1;4(6):526-548. doi: 10.1001/jamacardio.2018.4729.

PMID:
31066873
12.

XALIA-LEA: An observational study of venous thromboembolism treatment with rivaroxaban and standard anticoagulation in the Asia-Pacific, Eastern Europe, the Middle East, Africa and Latin America.

Kreutz R, Mantovani LG, Haas S, Monje D, Schneider J, Bugge JP, Gebel M, Tamm M, Ageno W, Turpie AGG.

Thromb Res. 2019 Apr;176:125-132. doi: 10.1016/j.thromres.2019.02.010. Epub 2019 Feb 13.

13.

Management and 1-Year Outcomes of Patients With Newly Diagnosed Atrial Fibrillation and Chronic Kidney Disease: Results From the Prospective GARFIELD - AF Registry.

Goto S, Angchaisuksiri P, Bassand JP, Camm AJ, Dominguez H, Illingworth L, Gibbs H, Goldhaber SZ, Goto S, Jing ZC, Haas S, Kayani G, Koretsune Y, Lim TW, Oh S, Sawhney JPS, Turpie AGG, van Eickels M, Verheugt FWA, Kakkar AK; GARFIELD‐AF Investigators.

J Am Heart Assoc. 2019 Feb 5;8(3):e010510. doi: 10.1161/JAHA.118.010510.

14.

Characteristics and Management of Patients with Venous Thromboembolism: The GARFIELD-VTE Registry.

Ageno W, Haas S, Weitz JI, Goldhaber SZ, Turpie AGG, Goto S, Angchaisuksiri P, Nielsen JD, Kayani G, Pieper KS, Schellong S, Bounameaux H, Mantovani LG, Prandoni P, Kakkar AK; GARFIELD-VTE investigators.

Thromb Haemost. 2019 Feb;119(2):319-327. doi: 10.1055/s-0038-1676611. Epub 2018 Dec 28.

PMID:
30593086
15.

XANTUS-EL: A real-world, prospective, observational study of patients treated with rivaroxaban for stroke prevention in atrial fibrillation in Eastern Europe, Middle East, Africa and Latin America.

Martínez CAA, Lanas F, Radaideh G, Kharabsheh SM, Lambelet M, Viaud MAL, Ziadeh NS, Turpie AGG; XANTUS Investigators.

Egypt Heart J. 2018 Dec;70(4):307-313. doi: 10.1016/j.ehj.2018.09.002. Epub 2018 Sep 24.

16.

Early Risks of Death, Stroke/Systemic Embolism, and Major Bleeding in Patients With Newly Diagnosed Atrial Fibrillation.

Bassand JP, Virdone S, Goldhaber SZ, Camm AJ, Fitzmaurice DA, Fox KAA, Goto S, Haas S, Hacke W, Kayani G, Mantovani LG, Misselwitz F, Pieper KS, Turpie AGG, van Eickels M, Verheugt FWA, Kakkar AK.

Circulation. 2019 Feb 5;139(6):787-798. doi: 10.1161/CIRCULATIONAHA.118.035012.

PMID:
30586740
17.

Impact of Prolonged Anticoagulation with Rivaroxaban on Provoked Venous Thromboembolism Recurrence: IMPROVE-VTE.

Coleman CI, Turpie AGG, Bunz TJ, Beyer-Westendorf J, Baker WL.

Am J Med. 2019 Apr;132(4):498-504. doi: 10.1016/j.amjmed.2018.11.040. Epub 2018 Dec 21.

PMID:
30582894
18.

Outcomes associated with non-recommended dosing of rivaroxaban: results from the XANTUS study.

Amarenco P, Haas S, Hess S, Kirchhof P, Lambelet M, Bach M, Turpie AGG, Camm AJ.

Eur Heart J Cardiovasc Pharmacother. 2019 Apr 1;5(2):70-79. doi: 10.1093/ehjcvp/pvy041.

PMID:
30423165
19.

Healthcare resource use in XALIA: A subgroup analysis of a non-interventional study of rivaroxaban versus standard anticoagulation for deep vein thrombosis.

Mantovani LG, Haas S, Kreutz R, Folkerts K, Gebel M, Monje D, Schneider J, van Eickels M, Sahin K, Zell E, Ageno W, Turpie AGG.

Eur J Intern Med. 2019 Mar;61:29-33. doi: 10.1016/j.ejim.2018.10.002. Epub 2018 Oct 19.

20.

Predictive value of venous thromboembolism (VTE)-BLEED to predict major bleeding and other adverse events in a practice-based cohort of patients with VTE: results of the XALIA study.

Klok FA, Barco S, Turpie AGG, Haas S, Kreutz R, Mantovani LG, Gebel M, Herpers M, Bugge JP, Kostantinides SV, Ageno W.

Br J Haematol. 2018 Nov;183(3):457-465. doi: 10.1111/bjh.15533. Epub 2018 Aug 19.

21.

Real-world vs. randomized trial outcomes in similar populations of rivaroxaban-treated patients with non-valvular atrial fibrillation in ROCKET AF and XANTUS.

Camm AJ, Amarenco P, Haas S, Hess S, Kirchhof P, Lambelet M, Bach M, Turpie AGG.

Europace. 2019 Mar 1;21(3):421-427. doi: 10.1093/europace/euy160.

PMID:
30052894
22.

Effectiveness and safety of rivaroxaban vs. warfarin in non-valvular atrial fibrillation patients with a non-sex-related CHA2DS2-VASc score of 1.

Coleman CI, Turpie AGG, Bunz TJ, Eriksson D, Sood NA, Baker WL.

Eur Heart J Cardiovasc Pharmacother. 2019 Apr 1;5(2):64-69. doi: 10.1093/ehjcvp/pvy025.

PMID:
30020424
23.

Global Prospective Safety Analysis of Rivaroxaban.

Kirchhof P, Radaideh G, Kim YH, Lanas F, Haas S, Amarenco P, Turpie AGG, Bach M, Lambelet M, Hess S, Camm AJ; Global XANTUS program Investigators.

J Am Coll Cardiol. 2018 Jul 10;72(2):141-153. doi: 10.1016/j.jacc.2018.04.058.

24.

Effectiveness and safety of rivaroxaban versus warfarin in patients with provoked venous thromboembolism.

Coleman CI, Turpie AGG, Bunz TJ, Beyer-Westendorf J.

J Thromb Thrombolysis. 2018 Oct;46(3):339-345. doi: 10.1007/s11239-018-1695-1.

PMID:
29881958
25.

Patient-Reported Treatment Experience with Oral Rivaroxaban: Results from the Noninterventional XALIA Study of Deep-Vein Thrombosis.

Cano S, Mantovani L, Folkerts K, Gebel M, Sahin K, Zell E, Monje D, Schneider J, Eickels MV, Haas S, Kreutz R, Ageno W, Turpie AGG.

TH Open. 2018 Apr 11;2(2):e139-e146. doi: 10.1055/s-0038-1641679. eCollection 2018 Apr.

26.

Effectiveness and Safety of Rivaroxaban Versus Warfarin in Frail Patients with Venous Thromboembolism.

Coleman CI, Turpie AGG, Bunz TJ, Beyer-Westendorf J.

Am J Med. 2018 Aug;131(8):933-938.e1. doi: 10.1016/j.amjmed.2018.02.015. Epub 2018 Mar 8.

PMID:
29526541
27.

Effectiveness and safety of outpatient rivaroxaban versus warfarin for treatment of venous thromboembolism in patients with a known primary hypercoagulable state.

Coleman CI, Turpie AGG, Bunz TJ, Baker WL, Beyer-Westendorf J.

Thromb Res. 2018 Mar;163:132-137. doi: 10.1016/j.thromres.2018.01.046. Epub 2018 Jan 31.

PMID:
29407625
28.

Risk factors for death, stroke, and bleeding in 28,628 patients from the GARFIELD-AF registry: Rationale for comprehensive management of atrial fibrillation.

Bassand JP, Accetta G, Al Mahmeed W, Corbalan R, Eikelboom J, Fitzmaurice DA, Fox KAA, Gao H, Goldhaber SZ, Goto S, Haas S, Kayani G, Pieper K, Turpie AGG, van Eickels M, Verheugt FWA, Kakkar AK; GARFIELD-AF Investigators.

PLoS One. 2018 Jan 25;13(1):e0191592. doi: 10.1371/journal.pone.0191592. eCollection 2018.

29.

Improved risk stratification of patients with atrial fibrillation: an integrated GARFIELD-AF tool for the prediction of mortality, stroke and bleed in patients with and without anticoagulation.

Fox KAA, Lucas JE, Pieper KS, Bassand JP, Camm AJ, Fitzmaurice DA, Goldhaber SZ, Goto S, Haas S, Hacke W, Kayani G, Oto A, Mantovani LG, Misselwitz F, Piccini JP, Turpie AGG, Verheugt FWA, Kakkar AK; GARFIELD-AF Investigators.

BMJ Open. 2017 Dec 21;7(12):e017157. doi: 10.1136/bmjopen-2017-017157.

30.

Outcomes after catheter ablation and cardioversion in patients with non-valvular atrial fibrillation: results from the prospective, observational XANTUS study.

Camm AJ, Turpie AGG, Hess S, Amarenco P, Lambelet M, Haas S, van Eickels M, Kirchhof P; XANTUS Investigators.

Europace. 2018 Jun 1;20(6):e87-e95. doi: 10.1093/europace/eux127.

PMID:
29016755
31.

Effect of extended-duration thromboprophylaxis on venous thromboembolism and major bleeding among acutely ill hospitalized medical patients: a bivariate analysis.

Chi G, Goldhaber SZ, Kittelson JM, Turpie AGG, Hernandez AF, Hull RD, Gold A, Curnutte JT, Cohen AT, Harrington RA, Gibson CM.

J Thromb Haemost. 2017 Oct;15(10):1913-1922. doi: 10.1111/jth.13783. Epub 2017 Sep 4.

32.

A post-marketing assessment of major bleeding in total hip and total knee replacement surgery patients receiving rivaroxaban.

Kwong LM, Turpie AGG, Tamayo S, Peacock WF, Yuan Z, Sicignano N, Hopf KP, Patel MR.

Curr Med Res Opin. 2017 Sep;33(9):1717-1723. doi: 10.1080/03007995.2017.1351935. Epub 2017 Jul 20.

PMID:
28678604
33.

Nonvitamin K antagonist oral anticoagulant use in patients with renal impairment.

Turpie AGG, Purdham D, Ciaccia A.

Ther Adv Cardiovasc Dis. 2017 Sep;11(9):243-256. doi: 10.1177/1753944717714921. Epub 2017 Jun 27. Review.

34.

Subgroup Analysis of Patients with Cancer in XALIA: A Noninterventional Study of Rivaroxaban versus Standard Anticoagulation for VTE.

Ageno W, Mantovani LG, Haas S, Kreutz R, Monje D, Schneider J, van Eickels M, Gebel M, Turpie AGG.

TH Open. 2017 Jun 28;1(1):e33-e42. doi: 10.1055/s-0037-1603924. eCollection 2017 Jun.

35.

Effectiveness and safety of rivaroxaban versus warfarin for treatment and prevention of recurrence of venous thromboembolism.

Coleman CI, Bunz TJ, Turpie AGG.

Thromb Haemost. 2017 Oct 5;117(10):1841-1847. doi: 10.1160/TH17-03-0210. Epub 2017 Jun 22.

PMID:
28640322
36.

Analysis of patients with deep vein thrombosis switched from standard therapy to rivaroxaban in the non-interventional XALIA study.

Turpie AGG, Mantovani LG, Haas S, Kreutz R, Monje D, Schneider J, van Eickels M, Gebel M, Ageno W.

Thromb Res. 2017 Jul;155:23-27. doi: 10.1016/j.thromres.2017.04.001. Epub 2017 Apr 13.

PMID:
28477534
37.

Rivaroxaban for venous thromboembolism prevention after major orthopedic surgery: translating trial data into routine clinical practice.

Beyer-Westendorf J, Mouret P, Turpie AG.

Orthop Res Rev. 2017 Jan 31;9:1-11. doi: 10.2147/ORR.S105227. eCollection 2017. Review.

38.

Quality of Vitamin K Antagonist Control and 1-Year Outcomes in Patients with Atrial Fibrillation: A Global Perspective from the GARFIELD-AF Registry.

Haas S, Ten Cate H, Accetta G, Angchaisuksiri P, Bassand JP, Camm AJ, Corbalan R, Darius H, Fitzmaurice DA, Goldhaber SZ, Goto S, Jacobson B, Kayani G, Mantovani LG, Misselwitz F, Pieper K, Schellong SM, Stepinska J, Turpie AG, van Eickels M, Kakkar AK; GARFIELD-AF Investigators.

PLoS One. 2016 Oct 28;11(10):e0164076. doi: 10.1371/journal.pone.0164076. eCollection 2016.

39.

Impact of Switching From a Vitamin K Antagonist to Rivaroxaban on Satisfaction With Anticoagulation Therapy: The XANTUS-ACTS Substudy.

Coleman CI, Haas S, Turpie AG, Kuhls S, Hess S, Evers T, Amarenco P, Kirchhof P, Camm AJ; XANTUS Investigators.

Clin Cardiol. 2016 Oct;39(10):565-569. doi: 10.1002/clc.22565. Epub 2016 Jun 30.

40.

Global Anticoagulant Registry in the Field - Venous Thromboembolism (GARFIELD-VTE). Rationale and design.

Weitz JI, Haas S, Ageno W, Angchaisuksiri P, Bounameaux H, Nielsen JD, Goldhaber SZ, Goto S, Kayani G, Mantovani L, Prandoni P, Schellong S, Turpie AG, Kakkar AK.

Thromb Haemost. 2016 Nov 30;116(6):1172-1179. Epub 2016 Sep 22.

PMID:
27656711
41.

Evolving antithrombotic treatment patterns for patients with newly diagnosed atrial fibrillation.

Camm AJ, Accetta G, Ambrosio G, Atar D, Bassand JP, Berge E, Cools F, Fitzmaurice DA, Goldhaber SZ, Goto S, Haas S, Kayani G, Koretsune Y, Mantovani LG, Misselwitz F, Oh S, Turpie AG, Verheugt FW, Kakkar AK; GARFIELD-AF Investigators.

Heart. 2017 Feb 15;103(4):307-314. doi: 10.1136/heartjnl-2016-309832. Epub 2016 Sep 19.

42.

Spotlight on real-world evidence for the treatment of DVT: XALIA.

Ageno W, Turpie AG.

Thromb Haemost. 2016 Sep 28;116(Suppl. 2):S41-S49. Epub 2016 Sep 14.

PMID:
27623684
43.

Two-year outcomes of patients with newly diagnosed atrial fibrillation: results from GARFIELD-AF.

Bassand JP, Accetta G, Camm AJ, Cools F, Fitzmaurice DA, Fox KA, Goldhaber SZ, Goto S, Haas S, Hacke W, Kayani G, Mantovani LG, Misselwitz F, Ten Cate H, Turpie AG, Verheugt FW, Kakkar AK; GARFIELD-AF Investigators.

Eur Heart J. 2016 Oct 7;37(38):2882-2889. Epub 2016 Jun 29.

44.

Bivariate evaluation of thromboembolism and bleeding in clinical trials of anticoagulants in patients with atrial fibrillation.

Kittelson JM, Steg PG, Halperin JL, Goldenberg NA, Schulman S, Spyropoulos AC, Kessler CM, Turpie AG, Cutler NR, Hiatt WR; Antithrombotic Trials Leadership and Steering (ATLAS) Group.

Thromb Haemost. 2016 Aug 30;116(3):544-53. doi: 10.1160/TH15-12-1000. Epub 2016 Jun 23.

PMID:
27346176
45.

The effects of timing of prophylaxis, type of anesthesia, and use of mechanical methods on outcome in major orthopedic surgery - subgroup analyses from 17,701 patients in the XAMOS study.

Haas S, Holberg G, Kreutz R, Lassen MR, Mantovani L, Haupt V, Vogtländer K, Turpie AG.

Vasc Health Risk Manag. 2016 May 18;12:209-18. doi: 10.2147/VHRM.S100293. eCollection 2016.

46.

Comparison of international normalized ratio audit parameters in patients enrolled in GARFIELD-AF and treated with vitamin K antagonists.

Fitzmaurice DA, Accetta G, Haas S, Kayani G, Lucas Luciardi H, Misselwitz F, Pieper K, Ten Cate H, Turpie AG, Kakkar AK; GARFIELD-AF Investigators.

Br J Haematol. 2016 Aug;174(4):610-23. doi: 10.1111/bjh.14084. Epub 2016 Apr 12.

PMID:
27071942
47.

Real life studies and good clinical practice - Authors' reply.

Ageno W, Mantovani LG, Haas S, Kreutz R, Monje D, Schneider J, van Eickels M, Gebel M, Zell E, Turpie AG.

Lancet Haematol. 2016 Apr;3(4):e160-1. doi: 10.1016/S2352-3026(16)00027-2. No abstract available.

PMID:
27063973
48.

Safety and effectiveness of oral rivaroxaban versus standard anticoagulation for the treatment of symptomatic deep-vein thrombosis (XALIA): an international, prospective, non-interventional study.

Ageno W, Mantovani LG, Haas S, Kreutz R, Monje D, Schneider J, van Eickels M, Gebel M, Zell E, Turpie AG.

Lancet Haematol. 2016 Jan;3(1):e12-21. doi: 10.1016/S2352-3026(15)00257-4. Epub 2015 Dec 8.

PMID:
26765643
49.

Rivaroxaban compared with standard thromboprophylaxis after major orthopaedic surgery: co-medication interactions.

Kreutz R, Haas S, Holberg G, Lassen MR, Mantovani LG, Schmidt A, Turpie AG.

Br J Clin Pharmacol. 2016 Apr;81(4):724-34. doi: 10.1111/bcp.12836. Epub 2016 Feb 12.

50.

Trends in Prescribing Oral Anticoagulants in Canada, 2008-2014.

Weitz JI, Semchuk W, Turpie AG, Fisher WD, Kong C, Ciaccia A, Cairns JA.

Clin Ther. 2015 Nov 1;37(11):2506-2514.e4. doi: 10.1016/j.clinthera.2015.09.008. Epub 2015 Oct 16.

Supplemental Content

Loading ...
Support Center